Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol: A valuable tool for evaluating progressive supranuclear palsy

Ruihui Weng, Xiaobo Wei, Bin Yu, Shuzhen Zhu, Xiaohua Yang, Fen Xie, Mahui Zhang, Ying Jiang, Zhong Ping Feng, Hong Shuo Sun, Ying Xia, Kunlin Jin, Piu Chan, Qing Wang, Xiaoya Gao

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Progressive supranuclear palsy (PSP) was previously thought as a cause of atypical Parkinsonism. Although Cystatin C (Cys C) and low-density cholesterol lipoprotein-C (LDL-C) are known to play critical roles in Parkinsonism, it is unknown whether they can be used as markers to distinguish PSP patients from healthy subjects and to determine disease severity. Methods: We conducted a cross-sectional study to determine plasma Cys C/HDL/LDL-C levels of 40 patients with PSP and 40 healthy age-matched controls. An extended battery of motor and neuropsychological tests, including the PSP-Rating Scale (PSPRS), the Non-Motor Symptoms Scale (NMSS), Geriatric Depression Scale (GDS) and Mini-Mental State Examination (MMSE), was used to evaluate the disease severity. Receiver operating characteristic (ROC) curves were adopted to assess the prognostic accuracy of Cys C/LDL-C levels in distinguishing PSP from healthy subjects. Results: Patients with PSP exhibited significantly higher plasma levels of Cys C and lower LDL-C. The levels of plasma Cys C were positively and inversely correlated with the PSPRS/NMSS and MMSE scores, respectively. The LDL-C/HDL-C ratio was positively associated with PSPRS/NMSS and GDS scores. The ROC curve for the combination of Cys C and LDL-C yielded a better accuracy for distinguishing PSP from healthy subjects than the separate curves for each parameter. Conclusions: Plasma Cys C and LDL-C may be valuable screening tools for differentiating PSP from healthy subjects; while they could be useful for the PSP intensifies and severity evaluation. A better understanding of Cys C and LDL-C may yield insights into the pathogenesis of PSP.

Original languageEnglish
Pages (from-to)37-42
Number of pages6
JournalParkinsonism and Related Disorders
Volume52
DOIs
StatePublished - 1 Jul 2018

Fingerprint

Progressive Supranuclear Palsy
Cystatin C
LDL Cholesterol
Healthy Volunteers
Parkinsonian Disorders
ROC Curve
Geriatrics
Depression
Neuropsychological Tests
Cross-Sectional Studies

Keywords

  • Cystatin C
  • Low-density lipoprotein cholesterol
  • Neurocognitive disorder
  • Progressive supranuclear palsy

Cite this

Weng, Ruihui ; Wei, Xiaobo ; Yu, Bin ; Zhu, Shuzhen ; Yang, Xiaohua ; Xie, Fen ; Zhang, Mahui ; Jiang, Ying ; Feng, Zhong Ping ; Sun, Hong Shuo ; Xia, Ying ; Jin, Kunlin ; Chan, Piu ; Wang, Qing ; Gao, Xiaoya. / Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol : A valuable tool for evaluating progressive supranuclear palsy. In: Parkinsonism and Related Disorders. 2018 ; Vol. 52. pp. 37-42.
@article{7a440959c67f455aa43dd3d128d626a6,
title = "Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol: A valuable tool for evaluating progressive supranuclear palsy",
abstract = "Introduction: Progressive supranuclear palsy (PSP) was previously thought as a cause of atypical Parkinsonism. Although Cystatin C (Cys C) and low-density cholesterol lipoprotein-C (LDL-C) are known to play critical roles in Parkinsonism, it is unknown whether they can be used as markers to distinguish PSP patients from healthy subjects and to determine disease severity. Methods: We conducted a cross-sectional study to determine plasma Cys C/HDL/LDL-C levels of 40 patients with PSP and 40 healthy age-matched controls. An extended battery of motor and neuropsychological tests, including the PSP-Rating Scale (PSPRS), the Non-Motor Symptoms Scale (NMSS), Geriatric Depression Scale (GDS) and Mini-Mental State Examination (MMSE), was used to evaluate the disease severity. Receiver operating characteristic (ROC) curves were adopted to assess the prognostic accuracy of Cys C/LDL-C levels in distinguishing PSP from healthy subjects. Results: Patients with PSP exhibited significantly higher plasma levels of Cys C and lower LDL-C. The levels of plasma Cys C were positively and inversely correlated with the PSPRS/NMSS and MMSE scores, respectively. The LDL-C/HDL-C ratio was positively associated with PSPRS/NMSS and GDS scores. The ROC curve for the combination of Cys C and LDL-C yielded a better accuracy for distinguishing PSP from healthy subjects than the separate curves for each parameter. Conclusions: Plasma Cys C and LDL-C may be valuable screening tools for differentiating PSP from healthy subjects; while they could be useful for the PSP intensifies and severity evaluation. A better understanding of Cys C and LDL-C may yield insights into the pathogenesis of PSP.",
keywords = "Cystatin C, Low-density lipoprotein cholesterol, Neurocognitive disorder, Progressive supranuclear palsy",
author = "Ruihui Weng and Xiaobo Wei and Bin Yu and Shuzhen Zhu and Xiaohua Yang and Fen Xie and Mahui Zhang and Ying Jiang and Feng, {Zhong Ping} and Sun, {Hong Shuo} and Ying Xia and Kunlin Jin and Piu Chan and Qing Wang and Xiaoya Gao",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.parkreldis.2018.03.014",
language = "English",
volume = "52",
pages = "37--42",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",

}

Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol : A valuable tool for evaluating progressive supranuclear palsy. / Weng, Ruihui; Wei, Xiaobo; Yu, Bin; Zhu, Shuzhen; Yang, Xiaohua; Xie, Fen; Zhang, Mahui; Jiang, Ying; Feng, Zhong Ping; Sun, Hong Shuo; Xia, Ying; Jin, Kunlin; Chan, Piu; Wang, Qing; Gao, Xiaoya.

In: Parkinsonism and Related Disorders, Vol. 52, 01.07.2018, p. 37-42.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol

T2 - A valuable tool for evaluating progressive supranuclear palsy

AU - Weng, Ruihui

AU - Wei, Xiaobo

AU - Yu, Bin

AU - Zhu, Shuzhen

AU - Yang, Xiaohua

AU - Xie, Fen

AU - Zhang, Mahui

AU - Jiang, Ying

AU - Feng, Zhong Ping

AU - Sun, Hong Shuo

AU - Xia, Ying

AU - Jin, Kunlin

AU - Chan, Piu

AU - Wang, Qing

AU - Gao, Xiaoya

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Introduction: Progressive supranuclear palsy (PSP) was previously thought as a cause of atypical Parkinsonism. Although Cystatin C (Cys C) and low-density cholesterol lipoprotein-C (LDL-C) are known to play critical roles in Parkinsonism, it is unknown whether they can be used as markers to distinguish PSP patients from healthy subjects and to determine disease severity. Methods: We conducted a cross-sectional study to determine plasma Cys C/HDL/LDL-C levels of 40 patients with PSP and 40 healthy age-matched controls. An extended battery of motor and neuropsychological tests, including the PSP-Rating Scale (PSPRS), the Non-Motor Symptoms Scale (NMSS), Geriatric Depression Scale (GDS) and Mini-Mental State Examination (MMSE), was used to evaluate the disease severity. Receiver operating characteristic (ROC) curves were adopted to assess the prognostic accuracy of Cys C/LDL-C levels in distinguishing PSP from healthy subjects. Results: Patients with PSP exhibited significantly higher plasma levels of Cys C and lower LDL-C. The levels of plasma Cys C were positively and inversely correlated with the PSPRS/NMSS and MMSE scores, respectively. The LDL-C/HDL-C ratio was positively associated with PSPRS/NMSS and GDS scores. The ROC curve for the combination of Cys C and LDL-C yielded a better accuracy for distinguishing PSP from healthy subjects than the separate curves for each parameter. Conclusions: Plasma Cys C and LDL-C may be valuable screening tools for differentiating PSP from healthy subjects; while they could be useful for the PSP intensifies and severity evaluation. A better understanding of Cys C and LDL-C may yield insights into the pathogenesis of PSP.

AB - Introduction: Progressive supranuclear palsy (PSP) was previously thought as a cause of atypical Parkinsonism. Although Cystatin C (Cys C) and low-density cholesterol lipoprotein-C (LDL-C) are known to play critical roles in Parkinsonism, it is unknown whether they can be used as markers to distinguish PSP patients from healthy subjects and to determine disease severity. Methods: We conducted a cross-sectional study to determine plasma Cys C/HDL/LDL-C levels of 40 patients with PSP and 40 healthy age-matched controls. An extended battery of motor and neuropsychological tests, including the PSP-Rating Scale (PSPRS), the Non-Motor Symptoms Scale (NMSS), Geriatric Depression Scale (GDS) and Mini-Mental State Examination (MMSE), was used to evaluate the disease severity. Receiver operating characteristic (ROC) curves were adopted to assess the prognostic accuracy of Cys C/LDL-C levels in distinguishing PSP from healthy subjects. Results: Patients with PSP exhibited significantly higher plasma levels of Cys C and lower LDL-C. The levels of plasma Cys C were positively and inversely correlated with the PSPRS/NMSS and MMSE scores, respectively. The LDL-C/HDL-C ratio was positively associated with PSPRS/NMSS and GDS scores. The ROC curve for the combination of Cys C and LDL-C yielded a better accuracy for distinguishing PSP from healthy subjects than the separate curves for each parameter. Conclusions: Plasma Cys C and LDL-C may be valuable screening tools for differentiating PSP from healthy subjects; while they could be useful for the PSP intensifies and severity evaluation. A better understanding of Cys C and LDL-C may yield insights into the pathogenesis of PSP.

KW - Cystatin C

KW - Low-density lipoprotein cholesterol

KW - Neurocognitive disorder

KW - Progressive supranuclear palsy

UR - http://www.scopus.com/inward/record.url?scp=85044281313&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2018.03.014

DO - 10.1016/j.parkreldis.2018.03.014

M3 - Article

C2 - 29574085

AN - SCOPUS:85044281313

VL - 52

SP - 37

EP - 42

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -